Trials / Active Not Recruiting
Active Not RecruitingNCT06677801
Immune Cell Subsets in SLE Patients Treated with Telitacicept
Changes of Immune Cell Subsets During the Treatment of Lupus with Telitacicept
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center cohort study. Patients with SLE who met the inclusion criteria were treated with tetanercept 160 mg once a week for a total of 24 weeks, and the clinical and laboratory indicators were collected before treatment, at the 4th week, at the 12th week, and at the 24th week, and blood samples were collected for the detection of immune cell subsets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Telitacicept 160mg | Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24. |
Timeline
- Start date
- 2024-10-11
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
- First posted
- 2024-11-07
- Last updated
- 2024-11-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06677801. Inclusion in this directory is not an endorsement.